{
  "name": "Cinclus Pharma Holding AB",
  "slug": "cinclus-pharma-holding-ab",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T02:31:40Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 11.90, volym 22683",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/cinclus-pharma-holding-ab/reports",
    "count": 11,
    "nasdaq_count": 11,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q4",
        "period_label": "2026 Q4",
        "date": "2026-07-02",
        "title": "Kvartalsrapport Q4 2026",
        "original_title": "Cinclus Pharma has Reached Enrollment Target in Phase III HEEALING1 Study - Topline Results Expected Q4 2026",
        "category": "Investor News",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5e84c2227e5fc14ba9779f51ef381d53&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2026",
            "title": "Kvartalsrapport Q4 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a282bcf2cda2ef27a9ceecc51f4a75b2a",
            "date": "2026-07-02",
            "period": "2026-q4",
            "form_type": "interim-report",
            "report_key": "2026:q4",
            "filename": "Cinclus_Pharma_has_Reached_Enrollment_Target_in_Phase_III_HEEALING1_Study_-_Topline_Results_Expe.pdf",
            "text_chars": 7132,
            "sha256": "a3ade84f3ebb56a475e5d9cba22fbf945d71ded11eb8759c7ce1f445395c7780",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/part-001.html",
                "chars": 7132
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-13",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Delårsrapport januari-mars 2026 - Fas III-studien närmar sig full rekrytering",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be3aea57a7868ab4df3cb80e874ac75dd&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac6dcc7bbc6692a0f752605df5f04d8c7",
            "date": "2026-05-13",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "Delarsrapport_Januari_Mars_2026.pdf",
            "text_chars": 62470,
            "sha256": "f3311b7e233e8d622d65baec7fcfd20c6cfb20db47f5867b579282da6260950f",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 62470
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-04-16",
        "title": "Årsredovisning 2025",
        "original_title": "Cinclus Pharmas offentliggör årsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b93dd7b9b8d76ef21dd41b14463b1fc99&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a76f761d15875030f49691cddf9148aa7",
            "date": "2026-04-16",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "Cinclus_Pharma_Arsredovisning_2025.pdf",
            "text_chars": 281267,
            "sha256": "7877b912af411f33be92b57647a1b704b119ac2f78845ef43255af100f8ac4bc",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 172584
              },
              {
                "number": 2,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 108681
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-18",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Meddelande om korrigering av Cinclus Pharmas bokslutskommuniké för 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bca8f507478de38bfd6c410b868f0d8f0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aaba771d2d1fe265b79612ee155efcae6",
            "date": "2026-02-18",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "Bokslutskommunike_2025.pdf",
            "text_chars": 95665,
            "sha256": "77b5757b975035b7c1264aa7d4b19696a6a8728fa9582c33f10ab218ab48c216",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 95665
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-20",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "A positive start to the Phase III study",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba561db31bee3b57137eaf7a01ba26e09&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a05ae3e9c05f619a0eb7dfed28ab19159",
            "date": "2025-11-20",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "Interim_Report_Cinclus_Pharma_Jan_Sep_2025_1.pdf",
            "text_chars": 101924,
            "sha256": "5f0c61e5739da3cc0e59df0afcf8d5a3c7eb54a4ad52037bd6cb26409c5ae795",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 101924
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-20",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Delårsrapport januari-juni 2025 - Stärkt position för framtida värdeskapande",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b1b37dbdf834ed3bc00471f73070318ab&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad3f2a1c26ea557b4f7522bb4bb94902f",
            "date": "2025-08-20",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "Delarsrapport_Cinclus_Pharma_Jan_Juni_2025_1.pdf",
            "text_chars": 95184,
            "sha256": "3bd0c85b4b77fcbd10ad07eeb719bb2a751b0bffa1f8e92dc8cee8e6a398e5d9",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 95184
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-20",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Delårsrapport januari-mars 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb2cbc8dcf4b4663856512d86f2a153bb&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a522e89c5664a1db22371aaf9c69463d2",
            "date": "2025-05-20",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "Cinclus_Pharma_Delarsrapport_Kvartal_1_2025.pdf",
            "text_chars": 87832,
            "sha256": "8a85b0ab839af5e12c95b5c540a2c1f0ce44634266fe922ef66c78020ac0c5a6",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 87832
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-30",
        "title": "Årsredovisning 2024",
        "original_title": "Meddelande om korrigering av Cinclus Pharmas offentliggjorda årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb2a8dd66cef72cfcfa1373ac38481409&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a394e7e17c7b2dcdbe58c1dbb2ba29122",
            "date": "2025-04-30",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "Cinclus_Pharma_Arsredovisning_2024_2.pdf",
            "text_chars": 342936,
            "sha256": "7cd593a96ce1e297e8c56d2afc904a9d469fc924881517ad61a704f46ba0258e",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 178763
              },
              {
                "number": 2,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 164171
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-20",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Bokslutskommuniké januari - december 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3d10e6c0b3d95c27fa9972ebca434110&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7f80acd423cf29ac5a7847d13df1c03a",
            "date": "2025-02-20",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "Bokslutskommunike_2024_Cinclus_Pharma.pdf",
            "text_chars": 92082,
            "sha256": "89d722bc452c3b5e5ee60f575da7fc0b2883a79ec60c48cf27ccb461d70f8ae8",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 92082
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-14",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Delårsrapport januari - september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba99df0ca79c2283630cd0ad4c55042dc&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a44e5a06d73f6dbbffa3866facd8f337d",
            "date": "2024-11-14",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_September_2024.pdf",
            "text_chars": 91562,
            "sha256": "b7243893f5c7fb4ff2bf11960b9e4b96ac38a00df1c81cb01f7c4780a4ac51aa",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 91562
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-29",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "CINCLUS PHARMA DELÅRSRAPPORT APRIL-JUNI 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b9cfcb0ad50550326861f2f8eef10edcd&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7c94962bd25075b3f3ab2a4e60e68e9d",
            "date": "2024-08-29",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_Juni_2024.pdf",
            "text_chars": 87625,
            "sha256": "5c0f583e66122910127e5377ca850253b3f7b7a228c0138a5c8540b88987d2d1",
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 87625
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 11,
  "nasdaq_report_count": 11,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Cinclus Pharma Holding AB",
    "identity": {
      "issuer": "XSpray Pharma AB (publ)",
      "lei": "549300NGRQCNZ3X4L157",
      "source": "FI insynsregister",
      "row_count": 49,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "Cinclus Pharma Holding AB",
      "query": "XSpray Pharma AB (publ)",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T02:31:40Z",
    "insider": {
      "transactions": 49,
      "all_export_rows": 49,
      "acquisitions": 13,
      "disposals": 8,
      "other": 28,
      "acquisition_value_sek": 8854879.37,
      "disposal_value_sek": 1395041.37,
      "characters": {
        "Avyttring": 8,
        "Förvärv": 13,
        "Lösen minskning": 4,
        "Teckning": 22,
        "Tilldelning": 2
      }
    },
    "short_selling": {
      "aggregate_percent": 1.08,
      "current_public_positions": 0,
      "historical_changes": 0,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX5372138",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/cinpha?id=TX5372138"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Cinclus Pharma Holding before IPO",
      "expected_name": "Cinclus Pharma Holding AB",
      "match_score": 74.66666666666666,
      "slug": "cinclus-pharma-holding",
      "url": "https://mfn.se/all/a/cinclus-pharma-holding",
      "metadata": {
        "website": "https://career.modularfinance.se"
      },
      "ticker_candidates": [],
      "attempts": [
        {
          "slug": "cinclus-pharma-holding-ab",
          "url": "https://mfn.se/all/a/cinclus-pharma-holding-ab",
          "status": "identity_mismatch",
          "title": "",
          "score": 0.0
        }
      ]
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX5372138",
      "asset_class": "SHARES",
      "isin": "SE0020388577",
      "symbol": "CINPHA",
      "company": "Cinclus Pharma Holding",
      "market": null,
      "last_sale_price": "SEK 11.90",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "XSpray Pharma AB (publ)",
      "lei": "549300NGRQCNZ3X4L157",
      "source": "FI insynsregister",
      "row_count": 49,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "Cinclus Pharma Holding AB",
      "query": "XSpray Pharma AB (publ)",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2026",
      "title": "Kvartalsrapport Q4 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a282bcf2cda2ef27a9ceecc51f4a75b2a",
      "date": "2026-07-02",
      "period": "2026-q4",
      "form_type": "interim-report",
      "report_key": "2026:q4",
      "filename": "Cinclus_Pharma_has_Reached_Enrollment_Target_in_Phase_III_HEEALING1_Study_-_Topline_Results_Expe.pdf",
      "text_chars": 7132,
      "sha256": "a3ade84f3ebb56a475e5d9cba22fbf945d71ded11eb8759c7ce1f445395c7780",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/part-001.html",
          "chars": 7132
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac6dcc7bbc6692a0f752605df5f04d8c7",
      "date": "2026-05-13",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "Delarsrapport_Januari_Mars_2026.pdf",
      "text_chars": 62470,
      "sha256": "f3311b7e233e8d622d65baec7fcfd20c6cfb20db47f5867b579282da6260950f",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 62470
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a76f761d15875030f49691cddf9148aa7",
      "date": "2026-04-16",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "Cinclus_Pharma_Arsredovisning_2025.pdf",
      "text_chars": 281267,
      "sha256": "7877b912af411f33be92b57647a1b704b119ac2f78845ef43255af100f8ac4bc",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 172584
        },
        {
          "number": 2,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 108681
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aaba771d2d1fe265b79612ee155efcae6",
      "date": "2026-02-18",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "Bokslutskommunike_2025.pdf",
      "text_chars": 95665,
      "sha256": "77b5757b975035b7c1264aa7d4b19696a6a8728fa9582c33f10ab218ab48c216",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 95665
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a05ae3e9c05f619a0eb7dfed28ab19159",
      "date": "2025-11-20",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "Interim_Report_Cinclus_Pharma_Jan_Sep_2025_1.pdf",
      "text_chars": 101924,
      "sha256": "5f0c61e5739da3cc0e59df0afcf8d5a3c7eb54a4ad52037bd6cb26409c5ae795",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 101924
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad3f2a1c26ea557b4f7522bb4bb94902f",
      "date": "2025-08-20",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "Delarsrapport_Cinclus_Pharma_Jan_Juni_2025_1.pdf",
      "text_chars": 95184,
      "sha256": "3bd0c85b4b77fcbd10ad07eeb719bb2a751b0bffa1f8e92dc8cee8e6a398e5d9",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 95184
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a522e89c5664a1db22371aaf9c69463d2",
      "date": "2025-05-20",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "Cinclus_Pharma_Delarsrapport_Kvartal_1_2025.pdf",
      "text_chars": 87832,
      "sha256": "8a85b0ab839af5e12c95b5c540a2c1f0ce44634266fe922ef66c78020ac0c5a6",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 87832
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a394e7e17c7b2dcdbe58c1dbb2ba29122",
      "date": "2025-04-30",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "Cinclus_Pharma_Arsredovisning_2024_2.pdf",
      "text_chars": 342936,
      "sha256": "7cd593a96ce1e297e8c56d2afc904a9d469fc924881517ad61a704f46ba0258e",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 178763
        },
        {
          "number": 2,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 164171
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7f80acd423cf29ac5a7847d13df1c03a",
      "date": "2025-02-20",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "Bokslutskommunike_2024_Cinclus_Pharma.pdf",
      "text_chars": 92082,
      "sha256": "89d722bc452c3b5e5ee60f575da7fc0b2883a79ec60c48cf27ccb461d70f8ae8",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 92082
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a44e5a06d73f6dbbffa3866facd8f337d",
      "date": "2024-11-14",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_September_2024.pdf",
      "text_chars": 91562,
      "sha256": "b7243893f5c7fb4ff2bf11960b9e4b96ac38a00df1c81cb01f7c4780a4ac51aa",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 91562
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7c94962bd25075b3f3ab2a4e60e68e9d",
      "date": "2024-08-29",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_Juni_2024.pdf",
      "text_chars": 87625,
      "sha256": "5c0f583e66122910127e5377ca850253b3f7b7a228c0138a5c8540b88987d2d1",
      "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 87625
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/cinclus-pharma-holding",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 2121,
      "sha256": "171bb0cf6acd4e9774563e8adf497e41e1f10da5c7b7170a3d86eae420a64bda",
      "url": "/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/cinclus-pharma-holding-ab/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 2121
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/cinclus-pharma-holding-ab/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/cinclus-pharma-holding-ab/market/history.json",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/cinclus-pharma-holding-ab/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/cinclus-pharma-holding-ab/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/cinclus-pharma-holding-ab/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/cinclus-pharma-holding-ab/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/cinclus-pharma-holding-ab/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/cinclus-pharma-holding-ab/finansinspektionen",
    "transaction_count": 49,
    "aggregate_short_percent": 1.08,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/cinclus-pharma-holding-ab/llms.txt",
  "json_url": "/company/cinclus-pharma-holding-ab/company.json",
  "document_index_url": "/company/cinclus-pharma-holding-ab/documents.json",
  "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab"
}